Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
Open Access
- 20 April 2010
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 12 (6), 510-516
- https://doi.org/10.1111/j.1463-1326.2010.01216.x
Abstract
Aim: Dapagliflozin is a stable, competitive, reversible, and highly selective inhibitor of sodium‐glucose co‐transporter 2, the major transporter responsible for renal glucose reabsorption. With an insulin‐independent mechanism of action, dapagliflozin is currently being developed for the treatment of type 2 diabetes mellitus (T2DM). This work aims to compare the efficacy of dapagliflozin, as measured by the change in hemoglobin A1c concentration (A1c) and body weight, and to determine the pharmacodynamic effects of dapagliflozin, as measured by urinary glucose excretion in early‐stage and late‐stage T2DM patient populations. Methods: A total of 151 early‐stage patients and 58 late‐stage patients with T2DM randomly assigned 10 or 20 mg once daily (QD) dapagliflozin treatment or placebo for 12 weeks from two phase 2 studies were included in the analysis. A1c, body weight, and urinary glucose were compared between the two patient populations. Results: Compared with the early‐stage population, patients in the late‐stage population had a longer duration of T2DM and higher baseline levels of A1c, body weight, fasting plasma glucose, and urinary glucose excretion. After 12 weeks of dapagliflozin treatment, A1c reduction, weight loss, and increased urinary glucose excretion from baseline were observed in both populations. Baseline A1c level impacted the A1c reduction after dapagliflozin treatment with a comparable effect in patients with early and late stage disease. Late‐stage patients had greater reduction in body weight. There was no statistically significant difference in the amount of urinary glucose excretion between the early‐stage and late‐stage patients. Conclusions: Dapagliflozin treatment at 10 and 20 mg QD for 12 weeks resulted in significant improvement in glycaemic control and body weight reduction in both early‐stage and late‐stage patients with T2DM. The findings suggest that dapagliflozin could be a promising treatment option for a wide range of patients with T2DM.Keywords
This publication has 11 references indexed in Scilit:
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin SensitizersDiabetes Care, 2009
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes MellitusCancer Cell, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Long‐term weight loss effects on all cause mortality in overweight/obese populationsObesity Reviews, 2007
- Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study)Diabetes Research and Clinical Practice, 2005
- Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 DiabetesDiabetes Care, 2004
- Pathophysiology and Pharmacological Treatment of Insulin ResistanceEndocrine Reviews, 2000
- Where is Malaysia in the midst of the Asian epidemic of diabetes mellitus?Diabetes Research and Clinical Practice, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998